Exenatide treatment for 6 months improves insulin sensitivity in adults with type 1 diabetes.
about
Heterologous Expression and Delivery of Biologically Active Exendin-4 by Lactobacillus paracasei L14Evolution of abnormal plasma glucagon responses to mixed-meal feedings in youth with type 1 diabetes during the first 2 years after diagnosisGLP-1 Agonists in Type 1 Diabetes Mellitus.Efficacy and safety of the glucagon-like peptide-1 receptor agonist liraglutide added to insulin therapy in poorly regulated patients with type 1 diabetes--a protocol for a randomised, double-blind, placebo-controlled study: the Lira-1 study.Stabilization of postprandial blood glucose fluctuations by addition of glucagon like polypeptide-analog administration to intensive insulin therapy.Lixisenatide accelerates restoration of normoglycemia and improves human beta-cell function and survival in diabetic immunodeficient NOD-scid IL-2rg(null) RIP-DTR mice engrafted with human islets.Markers of β-Cell Failure Predict Poor Glycemic Response to GLP-1 Receptor Agonist Therapy in Type 2 Diabetes.The GLP-1 receptor agonists exenatide and liraglutide activate Glucose transport by an AMPK-dependent mechanism.The treatment of type 1 diabetes mellitus with agents approved for type 2 diabetes mellitus.Towards an Earlier and Timely Diagnosis of Type 1 Diabetes: Is it Time to Change Criteria to Define Disease Onset?Exenatide: pharmacokinetics, clinical use, and future directions.Adjunctive Role of Glucagon-Like Peptide-1 Receptor Agonists in the Management of Type 1 Diabetes Mellitus.Latent autoimmune diabetes in adults (LADA) in Asian and European populations.Short-acting glucagon-like peptide-1 receptor agonists as add-on to insulin therapy in type 1 diabetes: A review.Combination therapy with GLP-1 receptor agonist and SGLT2 inhibitor.Effects of Insulin Plus Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) in Treating Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis.GLP-1 receptor agonists in type 1 diabetes: a proof-of-concept approach.Response to comment on Sarkar et al. Exenatide treatment for 6 months improves insulin sensitivity in adults with type 1 diabetes. Diabetes care 2014;37:666-670.Modifiable Risk Factors for Cardiovascular Disease in Children with Type 1 Diabetes: Can Early Intervention Prevent Future Cardiovascular Events?Long term (4 years) improved insulin sensitivity following islet cell transplant in type 1 diabetes.Exenatide improves ovarian and endometrial injury and preserves ovarian reserve in streptozocin induced diabetic rats.Effect of exenatide on postprandial glucose fluxes, lipolysis, and ß-cell function in non-diabetic, morbidly obese patients.The effects of add-on exenatide to insulin on glycemic variability and hypoglycemia in patients with type 1 diabetes mellitus.Addition of Liraglutide to Insulin in Patients With Type 1 Diabetes: A Randomized Placebo-Controlled Clinical Trial of 12 Weeks.Type 2 treatments for type 1 diabetes.Adjunctive therapy for glucose control in patients with type 1 diabetes.Protocol for Meal-time Administration of Exenatide for Glycaemic Control in Type 1 Diabetes Cases (The MAG1C trial): a randomised, double-blinded, placebo-controlled trial.Metabolic Control in Type 1 Diabetes: Is Adjunctive Therapy the Way Forward?Future and emerging therapiesTherapy of Type 1 Diabetes MellitusCounter-regulatory hormone responses to hypoglycaemia in people with type 1 diabetes after 4 weeks of treatment with liraglutide adjunct to insulin: a randomized, placebo-controlled, double-blind, crossover trial
P2860
Q28552845-89E72EF0-1972-4FF7-B444-05FE509538EBQ33646636-934962AD-D899-48BC-BAAC-B900FAD1A2D9Q34677451-84B5763E-7320-454D-A6E7-3B2A1C343CEAQ35331836-6C82F600-62DB-4E18-8F60-1C179B9DFB00Q35879321-C2F7F7E1-EE92-4915-8195-FE6697A5D408Q35994230-8EE54902-DBE2-4FC0-8EF1-014843A97D08Q36972891-8AD10467-CA30-4A21-A06C-E16AF749F67EQ37139985-9E787CC2-A674-43EC-AC0D-DAA999666671Q38580783-78E052CF-E546-48F1-94E1-EC0A34F99F84Q38607498-0D6C2F7D-5295-45E7-BB22-222DC2F82CB8Q38770746-69DA8D37-8F03-431A-8ABE-69AB7A4767B6Q38916838-C8518CE0-45C9-485F-8AF4-073C33695E8BQ39136099-701EE571-8C32-4015-A3FD-429B6FDF1161Q39140474-E0672D03-9BE7-4891-BA8F-4882461DE4A7Q39255963-2F9502F8-85A8-48CE-B148-47F52E352F7CQ39375164-4C756F09-C9D9-48D6-B377-315575D5D3F5Q41465810-8BF571BA-1247-41F8-96A1-70CC982340B2Q42908025-99560903-8E63-4A11-98A7-0116499AAB8EQ47159617-75B6C93F-73C6-4DF2-A537-DE71021E4CEBQ47325458-91D8CE74-7A98-4D1E-9112-BE303EC69DD2Q47579007-4D91134F-D767-4FCD-A34A-86BDCC0C26AFQ48190910-3C4335AB-4B39-491F-9ADC-96CE4993B6F8Q50070044-4307C748-25B5-4D73-9FED-BC642B300649Q50227623-61D112EB-0B89-473A-9B70-5DC49914C0F0Q53751922-CB3DBFB4-D5AF-48E3-A3AF-5A2200E5372EQ55234623-F6E1A5AA-E9F7-4E45-B0D4-B5735B37F2C9Q55689707-74D8D193-868A-44DC-8D78-80C511025BBAQ57157897-3271B517-AFE6-4BBD-B623-579760E49F51Q57160811-4BD69E37-D9DF-4D1C-AD80-75D02AC4F489Q57412611-25F3A26A-E569-4145-AEA8-9734B78C94D0Q57412827-B89C22C1-9095-41C1-9CD0-D4B37CF809F5
P2860
Exenatide treatment for 6 months improves insulin sensitivity in adults with type 1 diabetes.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Exenatide treatment for 6 mont ...... n adults with type 1 diabetes.
@en
Exenatide treatment for 6 mont ...... n adults with type 1 diabetes.
@nl
type
label
Exenatide treatment for 6 mont ...... n adults with type 1 diabetes.
@en
Exenatide treatment for 6 mont ...... n adults with type 1 diabetes.
@nl
prefLabel
Exenatide treatment for 6 mont ...... n adults with type 1 diabetes.
@en
Exenatide treatment for 6 mont ...... n adults with type 1 diabetes.
@nl
P2093
P2860
P356
P1433
P1476
Exenatide treatment for 6 mont ...... in adults with type 1 diabetes
@en
P2093
David M Harlan
Gayatri Sarkar
Kristina I Rother
May Alattar
Rebecca J Brown
P2860
P304
P356
10.2337/DC13-1473
P407
P577
2013-11-05T00:00:00Z